Cancer immunotherapy, or immuno-oncology, is a form of cancer treatment that uses the power of the body’s own immune system to prevent, control and eliminate cancer. Molecular Partners is proud to be part of the R&D community that makes #CancerImmunotherapyMonth possible. Our MP0317 and MP0533 programs, as well as our #SwitchDARPin platform, maximize the versatility of #DARPins to create novel therapeutics for #cancer patients worldwide. Learn more: https://bit.ly/3xjSQ3u
Molecular Partners’ Post
More Relevant Posts
-
UPCOMING WEBINAR - Immunotherapy Advancements: Transforming Cancer Treatment Join us as we dive into the revolutionary advancements in immunotherapy, a game-changer in cancer treatment. Key topics include: ✅ Remarkable efficacy of immunotherapy across melanoma, lung cancer, and more ✅ Overcoming resistance with innovative strategies and combination therapies ✅ Personalised treatments through precision immunotherapy ✅ Future trends, research, and challenges in the field 🌐 29 JULY 2024 at 3PM BST! Expand your knowledge and stay ahead in the fight against cancer. 💡 Register for FREE today! https://bit.ly/3ypxsK6 #Webinar #Immunotherapy #CancerResearch #HealthcareInnovation
To view or add a comment, sign in
-
-
Did you know prostate cancer is the second-leading cause of cancer death in American men, trailing only lung cancer? However, with advancements in immunotherapy, like Dendreon's, more men are given the chance to live longer after diagnosis. In fact, over 3.3 million men in the US diagnosed with prostate cancer are still alive today. To learn more about our innovative work in immunotherapy, visit: https://loom.ly/V-g2cQ8 #ProstateCancer #Immunotherapy #DendreonPharma
To view or add a comment, sign in
-
-
Clinical Research Associate | University Lecturer | Medical Sciences | Breast Cancer & Immunology | Keen on painting and organization
🌐 Colorectal cancer ranks as the third most prevalent cancer globally, being the third most common in men and the second most common in women worldwide. Learn more about colorectal cancer statistics at 🔗 https://lnkd.in/dqh4m2uQ
Did you know? Colorectal cancer is the third most common cancer in the United States. Make a gift during Colorectal Cancer Awareness Month to fund lifesaving immunotherapy research for colorectal cancer: https://bit.ly/49E5Hel #CancerResearch #Immunotherapy #ColorectalCancerAwarenessMonth #CRC
To view or add a comment, sign in
-
-
Lung cancer is the leading cause of cancer deaths in Wisconsin, more than pancreatic and colorectal cancers combined. Small-cell lung cancer (SCLC) is an especially aggressive type with very low survival rates. Find out how MCW researchers are using AHW Seed Grant Funding 🌱 to improve treatment for SCLC by finding ways to help the immune system better fight the cancer, in hopes of making treatments more effective and giving hope to those affected. Click to read more about this ⬇ project:https://lnkd.in/g4gsVG9v
To view or add a comment, sign in
-
-
November is Lung Cancer Awareness Month. Did you know lung cancer claims more lives than breast, pancreatic and prostate cancer combined? Learn more about lung cancer and how to lower your risk in our latest blog post. https://lnkd.in/gAriYKaB #LungCancerAwareness #QuitSmoking
To view or add a comment, sign in
-
Postgraduate student aspiring for a Formulation research & Development/Regulatory affairs internship in Pharma, aiming for a subsequent career in industrial organisations.
Hello connections, I'm thrilled to announce the publication of my first book chapter, "Lung Cancer Therapy: Synergistic Potential of PD-1/PD-L1 and CTLA-4 Inhibitors," in the book "Immunotherapy Against Lung Cancer". This milestone was achieved under the invaluable guidance of my mentor, Dr. Satish Shilpi. This chapter explores the cutting-edge advancements in immunotherapy, offering new hope and insights into the treatment of lung cancer. It's an honor to contribute to this significant field and to be part of a scientific community that's pushing the boundaries of what's possible in cancer therapy. You can access the chapter here, https://lnkd.in/giE9Y9mT #Publication #Immunotherapy #LungCancer #Research
To view or add a comment, sign in
-
-
Lung cancer care is quickly evolving, and biomarker-based therapies have opened up new possibilities for people with advanced non-small cell lung cancer (#NSCLC). ➡️ Learn about more about NSCLC from the Lung Cancer Foundation of America: https://amgen.ly/46WAW3V
To view or add a comment, sign in
-
November is Lung Cancer Awareness Month. In 2023, an estimated 238,340 people in the U.S. will be diagnosed with lung cancer, making it the second most commonly diagnosed cancer. Genelux is dedicated to not only raising awareness but advancing treatment in both Small Cell and Non-Small Cell Lung Cancer. #cancerresearch #stage4needsmore #cancer #lungcancer #lungcancerawarenessmonth
To view or add a comment, sign in
-
-
Moderna is exploring the potential of mRNA in immuno-oncology across various cancer types https://lnkd.in/gWTmSiNH #oncodaily #oncology #cancer #mRNAinImmunooncology #CancerTherapies #AACR24 #InnovativeMedicine #ImprovingOutcomes #MedicalTechnology
Moderna is exploring the potential of mRNA in immuno-oncology across various cancer types - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Lung cancer screening can save lives, but for some reason people at risk for the disease aren't doing it. Less than 6% of American eligible for lung cancer screening actually get screened. That compares to 72% for colon cancer and 76% for breast cancer. Ask your doctor about CyPath Lung https://lnkd.in/g7nRUkE2 and how it can complement screening to improve the detection of early-stage lung cancer. #cypathlung #LungCancer #lungcancerscreening #lungcancerawareness
To view or add a comment, sign in
-